Patents Assigned to IRM LLC
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7449582
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGF?, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2? kinases.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: November 11, 2008
    Assignee: IRM LLC
    Inventors: Qiang Ding, Yongping Xie, Nathanael S. Gray, Shuli You, Greg Chopiuk, Jiqing Jiang, Yi Liu, Ruo Steensma, Xing Wang, Taebo Sim
  • PYRROLIDONES WITH ANTI-HIV ACTIVITY
    Publication number: 20080255136
    Abstract: The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.
    Type: Application
    Filed: April 22, 2008
    Publication date: October 16, 2008
    Applicant: IRM LLC
    Inventors: Baogen Wu, Yun He, Truc Nguyen, Kelli L. Kuhen, David Archer Ellis, Tao Jiang, Xiaohui He, Kunyong Yang, Badry Bursulaya
  • HIGH THROUGHPUT PROCESSING SYSTEM AND METHOD OF USING
    Publication number: 20080253927
    Abstract: The present invention provides a system and method for high throughput processing using sample holders. The system has a plurality of work perimeters, with a rotational robot preferably associated with each work perimeter. At least one transfer station area is provided between adjacent work perimeters to facilitate robotic transfer of sample holders from one work perimeter to another area. Each work perimeter typically includes a plurality of defined station locations, with each station location positioned to be accessible by the robot associated with that area. In addition, each station location is typically configured to receive a device, such as an automated instrument or a holding nest. Device components are arranged at selected station locations according to specific application requirements to provide a flexible, robust, reliable, and accurate high throughput processing system.
    Type: Application
    Filed: June 23, 2008
    Publication date: October 16, 2008
    Applicant: IRM LLC
    Inventors: Kristina Marie Burow, Jeremy S. Caldwell, Robert Charles Downs, Scott Allan Lesley, James Kevin Mainquist, Andrew J. Meyer, Daniel G. Sipes, Mark Richard Weselak
  • Prohormone Convertase 1 Mutation Associated with Obesity
    Publication number: 20080250516
    Abstract: The invention provides novel prohormone convertase 1 mutants that have at least partially defective enzymatic activities. These mutant PC1 enzymes are defective in their autocatalytic activities, but appear to have normal ability in processing proGHRH to its mature form. Also provided in the invention are non-human animals that harbor such a mutant PC1 gene. These non-human animals are obese due to the mutant PC1 gene.
    Type: Application
    Filed: March 7, 2005
    Publication date: October 9, 2008
    Applicant: IRM LLC
    Inventors: Nicholas Gekakis, David Lloyd
  • LABELING REAGENT AND METHODS OF USE
    Publication number: 20080242838
    Abstract: The present invention provides compounds which are useful as multifunctional labels in proteomics studies. The labels of the present invention are both lysine specific and increase the overall sequence coverage obtained in polypeptide mapping experiments, by for example, increasing the ionization efficiencies of lysine-terminated tryptic fragments. In certain aspects, the labels of the present invention can be used to measure differential quantitation, as for example, deuterium(s) can easily be introduced during their synthesis. In one aspect, a C-terminal derivatized lysine biases the fragment ion intensities strongly toward C-terminal fragment ions, resulting in a highly simplified tandem mass spectrum. In further aspects, the number of lysine residues can be determined in a polypeptide.
    Type: Application
    Filed: May 7, 2007
    Publication date: October 2, 2008
    Applicant: IRM LLC
    Inventors: Eric C. Peters, Ansgar Brock, Christer Ericson
  • INHIBITORS OF CATHEPSIN S
    Publication number: 20080242671
    Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
    Type: Application
    Filed: March 25, 2008
    Publication date: October 2, 2008
    Applicant: IRM LLC
    Inventors: Hong Liu, Phillip Alper, Arnab Chatterjee, David Tully, Badry Bursulaya, David Woodmansee, Robert Epple, Jennifer Leslie Harris, Jun Li
  • Screening assay to identify modulators of the sleep/wake cycle
    Patent number: 7427489
    Abstract: Screening assays for identifying agents that modulate BK channel activity and further modulate the sleep/wake cycle in a subject, circadian regulated locomotor activity in a subject, or both are provided, as are agents identified using such screening assays. Also provided are methods of modulating the sleep/wake cycle in a subject and methods of modulating circadian regulated locomotor activity in a subject by administering an agent that modulates BK channel activity to the subject, for example, an agent identified by a screening assay as disclosed.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: September 23, 2008
    Assignees: The Scripps Research Institute, IRM LLC
    Inventors: Steve A. Kay, John B. Hogenesch, M. Fernanda Ceriani, Satchidananda Panda
  • 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors
    Publication number: 20080227783
    Abstract: The invention provides 5-substituted thiazol-2-yl amino compounds of Formula (I): pharmaceutical compositions comprising such compounds and the use of such compounds for the treatment or prevention of diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Ab 1, Aurora-A, Ber-Ab1, Bmx, CDKI/cyclinB, CHK2, Fes, FGFR3, Flt3, GSK3?, JNK1?1, Lck, MKK4 and TrkB kinases.
    Type: Application
    Filed: July 25, 2006
    Publication date: September 18, 2008
    Applicant: IRM LLC
    Inventors: Yongqin Wan, Nathanael S. Gray
  • Compounds and Compositions as Protein Kinase Inhibitors
    Publication number: 20080221192
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC kinases.
    Type: Application
    Filed: November 7, 2005
    Publication date: September 11, 2008
    Applicant: IRM LLC
    Inventors: Yongqin Wan, Yuan Mi, Yi Fan, Dai Cheng, Yi Liu, Nathanael S. Gray, Pamela Albaugh
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20080221098
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, c-Raf, Csk, Fes, FGFR, Flt3, Ikk, IR, JNK, Lck, Mkk, PKC, PKD, Rsk, SAPK, Syk, Trk, BTK, Src, EGFR, IGF, Mek, Ros and Tie2 kinases.
    Type: Application
    Filed: April 8, 2008
    Publication date: September 11, 2008
    Applicant: IRM LLC
    Inventors: Taebo Sim, Hyun Soo Lee, Pingda Ren, Qiang Ding, Yi Liu, Bing Li, Lintong Li, Xia Wang, Tetsuo Uno, Guobao Zhang, Nathanael Schiander Gray, Shuli You
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7423038
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders than involve abnormal activation of the Abl, Bcr-abl, Bmx, c-RAF, CSK, Fes, FGFR3, Flt3, GSK3?, IR, JNK1? 1, JNK2? 2, Lck, MKK4, MKK6, p70S6K, PDGFR?, Rsk1, SAPK2?, SAPK2?, Syk and Trk? kinases.
    Type: Grant
    Filed: June 23, 2005
    Date of Patent: September 9, 2008
    Assignee: IRM LLC (a Delaware Limited Liability Corporation)
    Inventors: Pingda Ren, Xia Wang, Nathanael Schiander Gray, Yi Liu, Taebo Sim
  • Compounds and compositions as protein kinase inhibitors
    Patent number: 7423031
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases and disorders associated with kinase activity, particularly diseases associated with the activity of CDK1, CDK2, CDK4, CDK5, GSK3?, Bcr-ab1, Flt-3, c-Kit, PDGFR?, Src, Mek1 and CK1.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: September 9, 2008
    Assignee: IRM LLC
    Inventors: Yongqin Wan, Nathanael Schiander Gray
  • Gripping mechanisms, apparatus and methods
    Patent number: 7422411
    Abstract: The present invention provides grasping mechanisms, gripper apparatus/systems, and related methods. Grasping mechanisms that include stops, support surfaces, and height adjusting surfaces to determine three translational axis positions of a grasped object are provided. In addition, grasping mechanisms that are resiliently coupled to other gripper apparatus components are also provided.
    Type: Grant
    Filed: September 6, 2006
    Date of Patent: September 9, 2008
    Assignee: IRM LLC
    Inventors: Robert Charles Downs, Mark Richard Weselak, James Kevin Mainquist
  • COMPOSITIONS AND METHODS FOR INDUCING OSTEOGENESIS
    Publication number: 20080214541
    Abstract: The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage.
    Type: Application
    Filed: September 20, 2007
    Publication date: September 4, 2008
    Applicants: IRM LLC, Scripps Research Institute
    Inventors: Xu Wu, Sheng Ding, Nathanael S. Gray
  • Immunosuppressant compounds and compositions
    Patent number: 7417065
    Abstract: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
    Type: Grant
    Filed: May 19, 2004
    Date of Patent: August 26, 2008
    Assignee: IRM LLC
    Inventors: Yuan Mi, Shifeng Pan, Nathanael Schiander Gray, Wenqi Gao, Yi Fan, Tao Jiang
  • Compounds and Compositions as Tpo Mimetics
    Publication number: 20080194668
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
    Type: Application
    Filed: August 15, 2006
    Publication date: August 14, 2008
    Applicant: IRM LLC
    Inventors: Thomas Marsilje, Wenshuo Lu, Phil Alper, Daniel Mutnick, Yun He
  • Compounds and Compositions as Protein Kinase Inhibitors
    Publication number: 20080188483
    Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, BMX, BTK, CHK2, c-RAF, CSK, c-SRC, Fes, FGFR3, Flt3, IKK?, IKK?, JNK2?2, Lck, Met, MKK4, MKK6, MST2, NEK2, p70S6K, PDGFR?, PKA, PKB?, PKD2, Rsk1, SAPK2?, SAPK2?, SAPK3, SGK, Tie2 and TrkB kinases.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 7, 2008
    Applicant: IRM LLC
    Inventors: Pingda Ren, Nathanael Schiander Gray, Xia Wang, Guobao Zhang
  • COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS
    Publication number: 20080176846
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.
    Type: Application
    Filed: October 16, 2007
    Publication date: July 24, 2008
    Applicant: IRM LLC
    Inventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
  • COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
    Publication number: 20080176881
    Abstract: The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.
    Type: Application
    Filed: November 20, 2007
    Publication date: July 24, 2008
    Applicant: IRM LLC
    Inventors: Pierre-Yves Michellys, Wei Pei, Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Tetsuo Uno, Yunho Jin, Tao Jiang
  • COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS
    Publication number: 20080176901
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
    Type: Application
    Filed: November 21, 2007
    Publication date: July 24, 2008
    Applicant: IRM LLC
    Inventors: David C. Tully, Arnab K. Chatterjee, Agnes Vidal, Badry Bursulaya, Glen Spraggon